Castle Biosciences Inc. has announced a new collaboration and license agreement with SciBase Holding AB to develop diagnostic tests for dermatologic diseases, with an initial focus on predicting flares in patients diagnosed with atopic dermatitis. The project will utilize SciBase's Electrical Impedance Spectroscopy technology. The collaboration aims to create a test that can pre-symptomatically predict flares, potentially allowing patients to begin rescue treatments to avoid or mitigate flare-ups. Castle Biosciences will focus its efforts in North America, while SciBase will concentrate on regions including the EU, Switzerland, United Arab Emirates, Japan, and South Korea. The financial terms include a single-digit royalty on Castle's gross margin and a milestone payment when sales hit $50 million annually. Results of the initial development project are yet to be presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.